TrivarX Limited (TRI) AI Stock Analysis

TrivarX Limited

(ASX:TRI)

Select Model

Rating:42Neutral

Price Target:AUD 0.01▲(10.00% Upside)

Action:upgraded

Date:09/25/26

The overall score of 42 reflects TrivarX's speculative profile as an early-stage, pre-revenue venture. The primary downward pressure stems from significant operational cash burn, a lack of top-line revenue, and strong bearish technical trends. While the company's debt-free balance sheet provides a critical runway for development, its extreme volatility and absolute reliance on external capital heavily restrict the stock's current rating.

Positive Factors

Low LeverageMinimal debt relative to equity reduces near-term solvency pressure and limits mandatory interest or repayment demands. This gives TrivarX greater balance-sheet flexibility while it addresses operating weaknesses, although low leverage alone does not establish a path to profitability.

Negative Factors

No Reported RevenueThree consecutive years of zero reported revenue provide no demonstrated revenue engine in the financial statements and leave the cost base uncovered. Without visible sales generation, durable operating scale and future self-funded growth remain unestablished over the next several quarters.

TrivarX Limited (TRI) vs. iShares MSCI Australia ETF (EWA)

Market Cap: AUD 3.35M
Dividend Yield: ―
Average Volume (3M): 705.07K
Price to Earnings (P/E): -0.0
Beta (1Y): 2.35
Revenue Growth: ―
EPS Growth: -336.84%
Country: Australia
Employees: 6
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Healthcare Information Services

TrivarX Limited Business Overview & Revenue Model

Company Description

Operating as a health technology enterprise, TrivarX Limited specializes in crafting artificial intelligence-driven, scientifically validated instruments designed for the assessment and identification of behavioral health disorders. Its market presen...

TrivarX Limited Financial Statement Overview

Summary

The score reflects TrivarX's pre-revenue status, characterized by zero revenue, expanding net losses, and ongoing operational cash burn. This risk is partially offset by a pristine, debt-free balance sheet with steady equity growth to fund near-term operations.

Income Statement

10Very Negative

Balance Sheet

75Positive

Cash Flow

15Very Negative

Financial statement breakdown
Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023
Income Statement
Total Revenue	0	0	0	0
Gross Profit	-6.47M	-6.47M	-52.47K	-93.13K
EBITDA	-1.95M	-1.95M	-1.89M	-1.13M
Net Income	-8.76M	-8.76M	-943.23K	-1.24M
Balance Sheet
Total Assets	16.53M	16.53M	13.48M	10.81M
Cash, Cash Equivalents and Short-Term Investments	2.44M	2.44M	1.25M	848.10K
Total Debt	128.14K	128.14K	169.03K	15.90K
Total Liabilities	565.64K	565.64K	831.22K	1.18M
Stockholders Equity	15.97M	15.97M	12.65M	9.88M
Cash Flow
Free Cash Flow	-542.85K	0	-189.74K	-3.70M
Operating Cash Flow	-1.51M	-1.51M	-189.74K	-1.48M
Investing Cash Flow	-1.17M	-1.17M	-2.09M	-2.85M
Financing Cash Flow	3.87M	3.87M	2.68M	4.32M

TrivarX Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price0.01

Price Trends

50DMA0.01Negative

100DMA0.02Negative

200DMA0.02Negative

Market Momentum

MACD-0.00Negative

RSI28.09Positive

STOCH50.00Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRI, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 28.09 is Positive, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:TRI.

TrivarX Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

AU:TRI against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AU:RHT	69Neutral	AUD 35.31M	23.13	13.72%	―	42.25%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:ICR	45Neutral	AUD 14.31M	-5.88	-416.53%	―	113.42%	29.17%
AU:AHE	42Neutral	AUD 8.93M	-0.45	-614.15%	―	-46.09%	70.70%
AU:TRI	42Neutral	AUD 10.38M	-0.01	-44.34%	―	―	-336.84%
AU:PKY	37Underperform	AUD 21.63M	-1.93	-18.10%	―	―	―
AU:PCK	27Underperform	AUD 16.32M	-1.80	-1688.04%	―	11.45%	0.69%

* Healthcare Sector Average

Performance Comparison

AU:TRI and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
AU:TRI	Trivarx Limited	0.01	-0.02	-64.29%
AU:RHT	Resonance Health Ltd	0.07	0.02	51.02%
AU:PKY	Opyl Ltd.	0.02	0.00	0.00%
AU:AHE	MedAdvisor Limited	0.01	-0.01	-46.15%
AU:ICR	InteliCare Holdings Limited	0.02	0.00	11.11%
AU:PCK	PainChek Ltd	0.08	-0.38	-83.04%

TrivarX Limited Corporate Events

TrivarX advances Stabl-Im platform toward clinical feasibility study

Sep 23, 2026

TrivarX has reported steady progress in the clinical and technical development of its Stabl-Im platform, with pre-clinical study designs completed and animal studies underway to support a planned clinical feasibility trial. The company has also final...

TrivarX Sets AGM Date and Director Nomination Deadline

Sep 21, 2026

TrivarX Limited has scheduled its Annual General Meeting for 19 November 2026, with further details to be provided to shareholders in forthcoming AGM materials. The company has also set 30 September 2026 as the deadline for written director nominatio...

TrivarX posts steep annual loss as revenue collapses but per-share asset backing rises

Aug 27, 2026

TrivarX Limited has reported a sharp deterioration in its financial performance for the year ended 30 June 2026, with revenue from ordinary activities plunging to $14,566 from $1.13 million a year earlier. The company’s net loss attributable to...

TrivarX refocuses on Stabl-Im as new CEO drives clinical push

Jul 28, 2026

TrivarX has sharpened its development strategy under new chief executive Dr Danielle Meyrick, prioritising disciplined clinical execution and capital allocation around its Stabl-Im imaging platform while limiting near-term spend on mental health tech...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 25, 2026

TrivarX Limited AI Stock Analysis